Cerenome

Today, we are proud to officially rebrand from Plus Therapeutics to Cerenome! Our common stock also begins trading today on the Nasdaq Capital Market under the new ticker symbol #CNSY (previously PSTV). Our transition to #Cerenome represents a major milestone in our company's evolution: moving from a #radiotherapeutics-focused developer to an integrated #CNSoncology company. By combining "cere" (representing the brain/central nervous system) with "nome" (signifying biological insight and data), our new name reflects our dedication to addressing the complex challenges of CNS cancers through a unified approach. While our name and ticker have changed, our commitment to patients, researchers, and clinicians remains stronger than ever. Discover our new look and learn more on our brand new website: www.cerenome.com #CancerDiagnostics #Nasdaq #PrecisionMedicine Nasdaq Exchange #Rebrand

#PlusTherapeutics announces that its corporate rebrand to #Cerenome will be completed as scheduled. Effective on Monday, August 3, 2026, #PSTV's name will become Cerenome, Inc. and its common stock will begin trading on the Nasdaq Capital Market under the new ticker symbol #CNSY. The new name reflects the Company's de facto evolution from a therapeutics-focused organization into an integrated CNS oncology company. Cerenome integrates #precisiondiagnostics, targeted therapeutics, and #AI to improve how CNS cancers are detected, treated, and understood. Full press release here: https://lnkd.in/et7Z-4Y3 #Nasdaq #PSTV Nasdaq Exchange #CNSOncology CNSide Diagnostics

On August 3, #PlusTherapeutics will officially become Cerenome (Nasdaq: #CNSY). As our President and CEO Dr. Marc Hedrick discusses in the video below, the foundation of the #Cerenome platform is designed to approach central nervous system (CNS) cancer as a solvable system by: - Advancing our lead drug #REYOBIQ™ through late-stage development - Bringing to market a complete portfolio of cerebrospinal fluid (CSF) diagnostic solutions under the CNSide Diagnostics brand - Using native #AI and novel data insights to drive strategy, operations, pipeline development, and partnering Read our mid-year business update and shareholder letter to learn more as we prepare for this exciting transition: - Business Update: https://lnkd.in/e2yWns5N - Shareholder Letter: https://lnkd.in/eFwKqD5N #CNSide #Nasdaq #CNSCancers

#PlusTherapeutics announces scientific presentations and sponsored symposium at the 2026 SNO/ASCO CNS Metastases Conference that will highlight research across its #REYOBIQ™ clinical development program and CNSide Diagnostics' cerebrospinal fluid diagnostic platform. #PSTV and #CNSide will also host a sponsored symposium titled “Redefining the Management of Leptomeningeal Metastases: Integrating Diagnostics, Molecular Insights, and Emerging Therapies” that will bring together leading key opinion leaders to discuss the evolving management of #leptomeningealmetastases. Learn more here: https://lnkd.in/dh6vABB6 Pre-register or request a copy of the symposium recording here: https://lnkd.in/dqiPRujq #NeuroOncology #BrainMetastases #CancerResearch #Oncology #SNO #ASCO Society for Neuro-Oncology, American Society of Clinical Oncology (ASCO)

Coming August 3rd: Our new identity from #PlusTherapeutics to #Cerenome reflects a natural evolution. We are more than a therapeutics company - we are an integrated #CNSOncology platform advancing diagnostics, therapeutics, and clinical data, designed to transform CNS cancer care. Our Vision for the future: CNS cancers have historically been considered some of the most difficult challenges in medicine. But we 𝐓𝐡𝐢𝐧𝐤 𝐢𝐭 𝐬𝐨𝐥𝐯𝐚𝐛𝐥𝐞. Learn more: https://lnkd.in/eiPTKKBP Letter from the CEO regarding the rebrand: https://lnkd.in/eK8w6KsC Effective August 3, 2026, Plus Therapeutics will change its corporate name to Cerenome, Inc. and begin trading under the Nasdaq ticker symbol #CNSY. Until that date, the Company will continue to operate as Plus Therapeutics and trade under the ticker symbol #PSTV. #Nasdaq #CancerResearch

#PlusTherapeutics announces that it has signed a regional agreement with Medical Mutual effective July 1, 2026, covering approximately 1.2 million people throughout #Ohio and #Kentucky, to provide the CNSide Diagnostics Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. This brings #CNSide CSF TCE assay total contracted coverage to approximately 127 million people. Full press release here: https://lnkd.in/eV6F6MSc #LeptomeningealMetastases #ClinicalTrials #PSTV #ClinicalTrial

#PlusTherapeutics announces a collaboration to integrate Genomic Testing Cooperative’s next-generation sequencing (NGS) technology into the CNSide Diagnostics' cerebrospinal fluid (CSF) assay platform. The collaboration is expected to enable comprehensive DNA and RNA profiling across hundreds of clinically relevant biomarkers from a single CSF specimen, extending #CNSide from guideline-recognized CTC enumeration into the guideline-recognized DNA and tumor-derived DNA analytic layer within one integrated platform. The collaboration advances #PSTV's three-pillar CNS #oncology strategy: - Targeted #radiotherapeutics led by #REYOBIQ™ (rhenium Re186 obisbemeda) - Precision diagnostics anchored by the CNSide CSF platform - #AI-enabled data analytics through the Company’s strategic partnership with Ephemeral Technologies Full press release here: https://lnkd.in/ehdnwQye

Today is #GlioblastomaAwarenessDay, an annual moment to raise awareness for #glioblastoma (#GBM) patients, their families and caregivers, and the incredible advocacy organizations driving crucial awareness and research forward every day of the year. #PlusTherapeutics is deeply committed to developing innovative approaches that aim to address some of the most challenging cancers of the central nervous system, including GBM. Learn more about our #braincancer clinical trials: https://lnkd.in/gYhPXbe4 #GoGray #ClinicalTrials National Brain Tumor Society American Brain Tumor Association #BrainTumorAwareness #BrainCancerAwareness #GBMDay

#PlusTherapeutics highlights the recent update to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Central Nervous System Cancers, including guidance relevant to #leptomeningealmetastases (LM), a serious and often underdiagnosed complication of advanced cancer. The updated #NCCN guidelines reinforce that cerebrospinal fluid (CSF) analysis remains a standard component of LM diagnosis and disease assessment and that, in patients receiving intrathecal therapy, CSF cytology is typically re-evaluated every four to eight weeks alongside MRI and clinical evaluation. Full press release here: https://lnkd.in/eeDwwrYP #ClinicalTrials #PSTV #ClinicalTrial #CNSide #CNSCancers CNSide Diagnostics

#PlusTherapeutics’ CEO & President, Dr. Marc Hedrick, penned a letter to shareholders outlining the significant milestone of our company's upcoming brand evolution to Cerenome coming on August 3rd. Read the full letter to learn more about our vision for the future of CNS oncology: https://lnkd.in/eKV3gWAQ #Cerenome #PSTV #CNSOncology